Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$57.02 USD

57.02
591,898

+0.73 (1.30%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $57.03 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Philips' (PHG) Q3 Earnings Down on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q3 top and bottom-line results reflect the negative impact of supply chain constraints, COVID lockdowns in China and the Russia-Ukraine war.

Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Abiomed's (ABMD) Latest Impella Offering Approved by the FDA

by Zacks Equity Research

Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.

Veeva Systems' (VEEV) New Launch to Streamline Clinical Data

by Zacks Equity Research

Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Combat Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Scorpio Tankers Inc. (STNG), AMN Healthcare (AMN), Ardmore (ASC) and Lancaster (LANC) are poised to gain.

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.

Veeva Systems' (VEEV) New Launch to Enhance Digital Trials

by Zacks Equity Research

Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.

BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence

by Zacks Equity Research

BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ

by Zacks Equity Research

Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.

Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

AMN vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Accuray's (ARAY) New Treatment Package to Boost Patient Outcome

by Zacks Equity Research

Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $113.46, moving +1.53% from the previous trading session.

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.

Indrajit Bandyopadhyay headshot

3 Medical Stocks to Buy in 2022 for Long-Term Resilience

by Indrajit Bandyopadhyay

Here we discuss two Medical companies, VRTX, ISRG and AMN, that may prove to be wealth creators for investors over the long term on the back of their strong fundamentals.

AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $111.75 in the latest trading session, marking a -1.51% move from the prior day.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Thermo Fisher (TMO) Launches New TaqPath Panel in Europe

by Zacks Equity Research

This panel of Thermo Fisher (TMO), apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast.

Charles River's (CRL) New Launch to Boost Gene Therapy Workflow

by Zacks Equity Research

Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.

If You Invested $1000 in AMN Healthcare Services a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.